{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:35:57Z","timestamp":1785332157584,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T00:00:00Z","timestamp":1423440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"AbbVie GmbH, Vienna Austria"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ample evidence shows that switching from one biological agent to another may prove effective when response to the first one is inadequate. Nevertheless, there are little data so far showing the efficacy and safety of adalimumab in patients with plaque psoriasis who previously received another biologic agent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We evaluated the 1\u2010year effectiveness, safety and quality\u2010of\u2010life outcomes patients with psoriasis who had switched to adalimumab from other biologic therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty\u2010two patients who participated in this Austrian multicenter study were treated with adalimumab over a 1\u2010year period, after switching from efalizumab, infliximab or etanercept.<\/jats:p><jats:p>Effectiveness was assessed using standardized tools for measurement of disease severity [Psoriasis Area and Severity Index (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>) and Nail Psoriasis Severity Index (<jats:styled-content style=\"fixed-case\">NAPSI<\/jats:styled-content>)] and quality of life [Dermatology Life Quality Index (<jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>)]. The study endpoints were evaluated using the all\u2010treated population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean percentage of improvement at the end of the study was 74.3% for <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>, 81.6% for <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> and 83.6% for <jats:styled-content style=\"fixed-case\">NAPSI<\/jats:styled-content>, demonstrating a considerable benefit of treatment with adalimumab. The safety profile observed was consistent with previous clinical trials for adalimumab, and no new safety signals were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adalimumab therapy in patients with plaque psoriasis previously treated with other biologic agents demonstrates effectiveness, safety and improvement in quality of life.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12981","type":"journal-article","created":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T10:28:55Z","timestamp":1423477735000},"page":"1742-1749","source":"Crossref","is-referenced-by-count":17,"title":["Adalimumab in the treatment of moderate\u2010to\u2010severe chronic plaque psoriasis in patients switching from other biologics"],"prefix":"10.1111","volume":"29","author":[{"given":"P.","family":"Sator","sequence":"first","affiliation":[{"name":"Department of Dermatology Hospital Hietzing with Neurologic Centre Rosenh\u00fcgel Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Richter","sequence":"additional","affiliation":[{"name":"Hospital Rudolfstiftung including site Semmelweis Clinic of Gynaecology Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Saxinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Wels\u2010Grieskirchen Wels\u2010Grieskirchen Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vasiljevic","sequence":"additional","affiliation":[{"name":"AbbVie Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Stingl","sequence":"additional","affiliation":[{"name":"Division of Immunology Allergy and Infectious Diseases (DIAID) Department of Dermatology Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503023320907"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2010.01.002"},{"key":"e_1_2_6_4_1","first-page":"1589","volume-title":"Textbook of Dermatology","author":"Camp RDR","year":"1998"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2012.07919.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12118"},{"key":"e_1_2_6_7_1","unstructured":"Raptiva (efalizumab).EPAR product information. [WWW document]2009. URLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000542\/WC500057853.pdf(last assessed: 30 November 2014)."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03944.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.08.040"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.03.009"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.933166"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740510026887"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.10.020"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000113943"},{"key":"e_1_2_6_15_1","first-page":"396","article-title":"An open\u2010label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab","volume":"10","author":"Vender R","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.01.004"},{"key":"e_1_2_6_17_1","unstructured":"Humira (adalimumab).EPAR product information. [WWW document]2014. URLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf(last assessed: 30 November 2014)."},{"key":"e_1_2_6_18_1","unstructured":"Remicade (infliximab).EPAR product information. [WWW document]2009. URLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000240\/WC500050888.pdf(last assessed: 30 November 2014)."},{"key":"e_1_2_6_19_1","unstructured":"Enbrel (etanercept).EPAR product information. [WWW document]2009. URLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf(last assessed: 30 November 2014)."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.3.15234"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.01.002"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04605.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq031"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.036"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202545"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12981","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12981","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:13:07Z","timestamp":1695492787000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/jdv.12981"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12981","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,9]]}}}